Skip to content

To find the number of cancer patients having lower than normal healthy red blood cell due to low iron in body, and how this affects their treatment

Prevalence of iron deficiency anemia in cancer patient and therapeutic outcomes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/06/043104
Enrollment
323
Registered
2022-06-08
Start date
Unknown
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

None listed

Sponsors

Dr Malini Mohan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Hemoglobin level less than or equal to 10 g/dL - Transferrin saturation - Any stage solid malignancies

Exclusion criteria

Exclusion criteria: - Age less than 18yrs - Pregnant women - any evidence of hemolysis - Active gastrointestinal bleeding (stool occult blood positive) - active infection requiring systemic antibiotics - HIV infection - active Tuberculosis infection - liver/ renal dysfunction - Grade 2 or higher based on National Cancer Institute Common Toxicity Criteria: Bilirubin >1.5 times normal, Transaminases >2.5 times normal), renal dysfunction (serum creatinine levels > or equal to 2.0 mg/dL) - Malignant Bone marrow infiltration -Received iron supplementation / blood transfusion in the preceding 4 weeks

Design outcomes

Primary

MeasureTime frame
Prevalence of patients with absolute and functional iron deficiency anemia Timepoint: 2 years

Secondary

MeasureTime frame
a)Best response to treatment - Response will be defined as proportion of patients achieving an increase in hemoglobin at any time from baseline to end of 12 weeks. Response criteria is defined as follows: - Complete response : increase in Hemoglobin level 2.0 g/dL above baseline, and/ or transfusion free. Partial response : increase in Hemoglobin level (1g/dL-2g/dL) above baseline Minor response : increase in Hemoglobin level ( 0.5 g/dL-1g/dL) above baseline b)Efficacy assessment with quality of life questionnaire (Functional assessment of cancer therapy- Anemia ( FACT An )) Timepoint: 2 years

Countries

India

Contacts

Public ContactDr Karthik Udupa

Kasturba Medical College Manipal

udupa.k@gmail.com9845317153

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026